Gujarat Themis Biosyn Share Price

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG) a unique consortium of five competing drug companies Themis Medicare Ltd., Kopran Ltd., Anant Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, Company was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corp., South Korea, brought in technology and finance for running GTBL.During 199596 the paidup share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year 201920, installed capacity of rifamysinS was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of antituberculosis products and other antibiotics in 2022.Company is presently engaged in the manufacturing of fermentationbased pharmaceutical intermediates and APIs. It is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin. The Company commenced its commercial production at its newly set up API Plant situated at 69/C, GIDC Industrial Estate, Vapi, in Valsad district of Gujarat with effect from 6 May, 2025. The multipurpose synthetic and fermentationbased API plant has been established for the production of various Active Pharmaceutical Ingredients (APIs) and Intermediates for use in the pharmaceutical industry.

As of Jun '26, Gujarat Themis Biosyn’s market capitalisation stood at ₹5,899.13 crores. Shareholding as of Jun '26 shows promoters holding 70.9%, with FIIs at 1.8%, DIIs at 1.1%, and public at 26.2%.